Clinical Trial Update: Study of AZD9291 in NSCLC Patients Harboring T790M Mutation Who Failed EGFR TKI and With Brain and/or LMS [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating AZD9291 (osimertinib) in non-small cell lung cancer patients with EGFR T790M mutation and brain or leptomeningeal metastase…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• AZD9291 (osimertinib)

Snippet

Sponsor: Samsung Medical Center | Conditions: Non-Small Cell Lung Cancer With EGFR T790M Mutation, With Brain and/or Leptomeningeal Metastasis | Phase 2 | Status: UNKNOWN